Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.34 |
| ▸ | LPL | P06858 | 6/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31387299 | 0.78 | IRAK4 (0.37) | IRAK4LPLLIPGFFAR1 | |
| SCHEMBL25200891 | 0.74 | IRAK4 (0.39) | IRAK4LPLLIPGFFAR1ROCK1 | |
| SCHEMBL23998384 | 0.72 | ALDH1A1 (0.37) | IRAK4LPLLIPGFFAR1 | |
| SCHEMBL20620663 | 0.71 | LIPG (0.39) | IRAK4LPLLIPGFFAR1 | |
| SCHEMBL4671691 | 0.70 | LPL (0.43) | IRAK4LPLLIPGFFAR1 | |
| SCHEMBL31489565 | 0.69 | LPL (0.33) | IRAK4LPLLIPG | |
| SCHEMBL517499 | 0.69 | LPL (0.52) | LPLLIPGFFAR1 | |
| SCHEMBL23712839 | 0.67 | POLB (0.39) | IRAK4 | |
| SCHEMBL29196621 | 0.67 | TSHR (0.41) | IRAK4 | |
| SCHEMBL23316404 | 0.66 | FFAR1 (0.38) | IRAK4LPLLIPGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042879-A1 | HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. | 2025-02-06 | — | — | US | disclosed |
| EP-4436665-A1 | HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME | Rgenta Therapeutics, Inc. (US) | 2024-10-02 | — | — | EP | disclosed |
| WO-2023092149-A1 | HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
| WO-2023092149-A1 | HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME | RGENTA THERAPEUTICS, INC. (US) | 2023-05-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250042879-A1 | HETEROCYCLIC SUBSTITUTED 1,3,4-THIADIAZOLE AND PYRIDAZINE COMPOUNDS AND METHODS OF USING THE SAME | RBM17, SF3B5, SF3A2 | IRAK4 1920/4885LPL 2502/4885LIPG 2815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.